EUVIMEDEUVIMED entdecken
Crossref

Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes

Anna Maria Militello, Giulia Orsi, Alessandro Cavaliere, Monica Niger, Antonio Avallone, Lisa Salvatore, Giampaolo Tortora, Ilario Giovanni Rapposelli, Guido Giordano, Silvia Noventa, Elisa Giommoni, Silvia Bozzarelli und 8 weitere

Cancer Chemotherapy and Pharmacology · 2023

DOI: 10.1007/s00280-023-04585-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2023. Verfasst von Anna Maria Militello und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, IRCCS San Raffaele Scientific Institute, Vita-Salute University, Via Olgettina 60, 20123, Milan, Italy. Hauptthemen laut MEDLINE: Pancreatic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The clinical outcome and the efficacy of chemotherapy in pancreatic cancer patients with BRCA1/2 Variants of Unknown Significance (VUS) is unknown. We explored the effects of chemotherapy with or without Platinum in non metastatic and metastatic pancreatic cancer patients with BRCA1/2 VUS. METHODS: A retrospective analysis of non-metastatic or metastatic pancreatic cancer patients with gBRCA1/2 VUS treated in 13 Italian centers between November 2015 and December 2020 was performed. All patients were assessed for toxicity and RECIST 1.1 response. Metastatic patients were evaluated for survival outcome. RESULTS: 30 pancreatic cancer patients with gBRCA1/2 VUS were considered: 20 were M+ and 10 were non-M+. Pl-CT was recommended to 16 patients: 10 M+ (6 FOLFIRINOX and 4 PAXG) and 6 non-M+ (3 FOLFIRINOX and 3 PAXG); 11 patients received Nabpaclitaxel-Gemcitabine (AG; 8 M+) and 3 patients (2 M+) were treated with Gemcitabine (G). The RECIST 1.1 response rate was 27% for AG and 44% for Pl-CT (22% for (m) FOLFIRINOX and 71% PAXG). 1 year Progression-Free Survival was 37.5% for patients treated with AG and 33% in the Pl-CT subgroup. Median Overall Survival (OS) was 23.5 months for patients treated with AG and 14 months for the Pl-CT subgroup. 1 Year and 2 Year OS were numerically better for AG (1 Year OS: 75% vs 60% and 2 Year OS: 50% and 20% in AG and Pl-CT subgroups, respectively) as well. CONCLUSIONS: Pl-CT does not seem to be associated with a better outcome compared to AG chemotherapy in PDAC patients with BRCA 1/2 VUS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsHumansGenes, BRCA2BRCA1 ProteinAntineoplastic Combined Chemotherapy ProtocolsRetrospective StudiesBRCA2 Protein

Stichwörter der Autor:innen

BRCA Variants of Unknown Significance (VUS)Chemotherapy responseChemotherapy toxicityPancreatic cancerPlatinum chemotherapy

Substanzen

BRCA1 protein, humanBRCA1 ProteinBRCA2 protein, humanBRCA2 Protein

Autor:innen und Institutionen

  • Department of Medical Oncology, IRCCS San Raffaele Scientific Institute, Vita-Salute University, Via Olgettina 60, 20123, Milan, Italy.
  • Pancreas Translational & Clinical Research Center, San Raffaele Scientific Institute, Milan, Italy.
  • Department of Oncology, University of Torino, Candiolo, Italy.
  • Candiolo Cancer Institute, FPO - IRCCS Candiolo, Candiolo, Italy.
  • Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Dei Tumori Di Milano, Milan, Italy.
  • Biologia Cellulare e Bioterapie, Istituto Nazionale per lo Studio e la Cura dei Tumori ''Fondazione Giovanni Pascale'' - IRCCS, Naples, Italy.

ORCID-Profile: Michele Reni

Zitieren

APA

Militello, A. M., Orsi, G., Cavaliere, A., Niger, M., Avallone, A., Salvatore, L., Tortora, G., Rapposelli, I. G., Giordano, G., Noventa, S., Giommoni, E., Bozzarelli, S., Macchini, M., Peretti, U., Procaccio, L., Puccini, A., Cascinu, S., Montagna, C., Milella, M., & Reni, M. (2023). Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-023-04585-w

Vancouver

Militello AM, Orsi G, Cavaliere A, Niger M, Avallone A, Salvatore L, et al. Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes. Cancer Chemotherapy and Pharmacology. 2023. doi:10.1007/s00280-023-04585-w

BibTeX
@article{Militello2023,
  author = {Militello, Anna Maria and Orsi, Giulia and Cavaliere, Alessandro and Niger, Monica and Avallone, Antonio and Salvatore, Lisa and Tortora, Giampaolo and Rapposelli, Ilario Giovanni and Giordano, Guido and Noventa, Silvia and Giommoni, Elisa and Bozzarelli, Silvia and Macchini, Marina and Peretti, Umberto and Procaccio, Letizia and Puccini, Alberto and Cascinu, Stefano and Montagna, Cristina and Milella, Michele and Reni, Michele},
  title = {Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2023},
  doi = {10.1007/s00280-023-04585-w}
}
Kostenlos starten →